Industry
Drug Manufacturers - Specialty & Generic
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Loading...
Open
2.69
Mkt cap
5.4M
Volume
85K
High
2.81
P/E Ratio
-0.02
52-wk high
608.00
Low
2.61
Div yield
N/A
52-wk low
2.11
Portfolio Pulse from
November 06, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Insights
June 19, 2024 | 4:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.